The influenza virus polymerase transcribes and replicates the viral genome. The proper timing 17 and balance of polymerase activity is important for successful replication. We previously showed 18 that phosphorylation regulates genome replication by controlling assembly of the replication 19 machinery (Mondal, et al. 2017). However, it remained unclear whether phosphorylation directly 20 regulated polymerase activity. Here we identified polymerase phosphosites that control its 21 function. Mutating phosphosites in the catalytic subunit PB1 altered polymerase activity and virus 22 replication. Biochemical analyses revealed phosphorylation events that disrupted global 23 polymerase function by blocking the NTP entry channel or preventing RNA binding. We also 24 identified a regulatory site that split polymerase function by specifically suppressing transcription. 25
Introduction 31
All RNA viruses encode machinery both to express viral transcripts and to replicate genomes. 32
Negative sense RNA viruses must first transcribe using virally-encoded RNA-dependent RNA 33 polymerases (RdRPs) that are packaged into virions. The viral RdRP subsequently replicates the 34 genome, often with the help of protein products from the recently produced mRNA. Regulating 35 the balance and timing of transcription and replication is crucial for successful infection. 36
Viruses employ diverse strategies to control the abundance of virally-derived RNAs. Many RNA 37 viruses rely on RdRP co-factors whose activity is dynamically regulated by post-translational 38 modifications. For example, the Ebola virus polymerase is regulated by the viral transcription all virally-derived RNA occurs (Herz et al., 1981; Jackson et al., 1982) . Infection initiates with a 60 pioneering round of transcription from the incoming RNPs. The viral polymerase performs cap-61 snatching where a short capped oligonucleotide derived from the host is used to prime 62 transcription (Bouloy et al., 1978; Plotch et al., 1979) . Unlike transcription, replication initiates in 63 a primer-independent fashion to create a positive-sense intermediate (cRNA) that serves as a 64 template for vRNA production (Hay et al., 1977) . Replication requires concomitant assembly into 65 newly formed RNPs to stabilize the viral genome (Vreede et al., 2004) . Newly formed vRNPs can 66 either be packaged into virions or serve as templates for additional rounds of transcription or 67 replication. 68
The processes regulating polymerase activity are not fully defined. Some regulation simply 69 requires the production of specific viral proteins or RNAs. The stable products from incoming 70
RNPs are viral mRNAs, even though incoming RNPs are capable of making cRNA as well. 71
Replication occurs later when newly synthesized NP is able to coat cRNA genomes and protect 72 them from degradation (Vreede et al., 2004) . Newly synthesized viral polymerase binds nascent 73 RNA products and interacts with cRNP-bound polymerases to stimulate production of full-length 74 vRNA (Fodor and during influenza virus infection (Dawson and Mehle, 2018) . Like many other RNA viruses, 79 phosphorylation of viral proteins plays a key role in regulating the influenza virus replication 80 machinery. We have previously shown that phosphorylation of NP regulates de novo RNP 81 assembly (Mondal et al., 2015 (Mondal et al., , 2017 . The protein kinase C (PKC) family, and PKCd in particular, 82 phosphorylates NP at its homotypic interface to block NP oligomerization. This is proposed to 83 create a pool of monomeric NP that is subsequently licensed for oligomerization by a cellular 84 phosphatase, possibly CDC25B (Cui et al., 2018) . 85
PKCd phospho-regulates NP oligomerization and by extension the ability of the polymerase to 86 replicate the viral genome (Mondal et al., 2017) . These studies also provided intriguing data 87 suggesting that the polymerase may also be phosphorylated. Whether phosphorylation directly 88 regulates polymerase activity is unclear. Here we extensively map phosphorylation sites on the 89 polymerase subunit PB1 and characterize their function. PB1 is the structural and catalytic core 90 of the enzyme, and we define PB1 phospho-sites that inhibit RNA synthesis by blocking global 91 catalytic function or genomic RNA binding. We also identified a regulatory site that split the 92 function of the polymerase; mimicking phosphorylation at PB1 S673 suppressed transcription 93 without altering genome replication. Viruses encoding phospho-ablative mutants at these 94 positions displayed altered replication kinetics, whereas phospho-mimetic mutants did not 95 replicate. These data demonstrate that phosphorylation directly regulates viral polymerase activity 96 and may provide a mechanism to bias populations of polymerase towards replication or 97 transcription. 98
Results: 99

Phosphorylation alters activity of influenza virus polymerase 100
We had previously shown that PKCd regulates RNP assembly by modifying NP and preventing 101 premature NP oligomerization (Mondal et al., 2017) . This work also revealed slower migrating 102 species of the PB2 polymerase subunit that raised the possibility that the polymerase itself was 103 phosphorylated in the presence of PKCd. To test this possibility, we assessed the migrations 104 patterns of PB2 before or after phosphatase treatment. We sought to study direct effects on the 105 viral polymerase, but this cannot be done in the context of an RNP as PKCd regulates NP function. 106
We eliminated this confounder by using a short vRNA template (vNP77) that does not require NP 107 for replication or transcription, and thus decouples RNP assembly from RNA synthesis activities 108 (Turrell et al., 2013) . The viral polymerase was expressed in cells with constitutively active PKCd 109 and vNP77 and immuno-purified samples were analyzed by western blot ( Figure 1A ). Slower 110 migrating species were detected for PB2, confirming our prior results. Treating samples with 111 phosphatase collapsed these species into a single band migrating at the expected position for 112 PB2, suggesting that PB2 is phosphorylated. A shorter exposure of the same gel confirmed 113 equivalent loading of PB2. 114
We then asked whether PKCd expression affects RNA synthesis activities of the polymerase. The 115 viral polymerase and vNP77 were expressed in cells in the presence or absence of constitutively-116 active PKCd. Primer extension analysis of RNA extracted from these samples quantified 117 transcription (mRNA) and replication (vRNA) products. Co-expression of PKCd significantly 118 impaired production of viral transcripts and replication products, without altering viral protein levels 119 ( Figure 1B ). Together, these data indicate that the viral polymerase is phosphorylated and these 120 modifications may alter intrinsic polymerase activity. 121
The polymerase core is phosphorylated at highly conserved sites 122
Given its potential to regulate polymerase activity, we performed a series of complementary 123 experiments to extensively characterize polymerase phosphorylation ( Figure 2A ). We repeated 124 experiments where phosphorylation was shown at affect polymerase function by expressing the 125 viral polymerase, vNP77 and activated PKCd in 293T cells. Polymerase was immuno-purified and 126 analyzed phospho-peptide mass spectrometry (MS) in two independent experiments. In parallel, 127 we analyzed samples from infected cells. Polymerase phosphorylation status may vary across 128 multiple rounds of infection; therefore, we collected samples from low and high MOI infections 129 performed in A549 cells and analyzed whole-cell lysate. We also allowed for the possibility that 130 phosphorylation patterns change throughout a single infection by analyzing RNP 131 immunoprecipitations from both individual and pooled time points from synchronized infections. 132
The amount of each sample used in the pooled lysate was adjusted to approximate similar levels 133 of viral protein for all time points. These approaches allowed for high-confidence identification of 134 phosphorylation sites on the viral polymerase (Supplemental Table 1 ). 135
We focused our analysis on PB1, the subunit that catalyzes RNA synthesis. A total of 13 136 phosphorylated residues were identified on PB1 in all experimental conditions, of which 8 were 137 also detected in the context of infection (Supplemental Table 1 ). Phosphorylation occurred 138 primarily on threonine and serine residues, with only one phospho-tyrosine identified. Most of the 139 phospho-sites are highly conserved in human H1N1 and H3N2 strains and highly pathogenic 140 H5N1 strains ( Figure 2B ). Some of the identified phosphorylation sites overlapped between our 141 infected and transfected cells (S216, T223, S673), whereas others were identified only during 142 infection (T228, Y253, T570, S712, S720) or when polymerase was co-expressed with PKCd 143 (S478, S384). We placed high priority on the four sites that we identified in at least two separate 144 experiments: PB1 S216, T223, S384, and S673. These phospho-sites could be broadly 145 categorized into those that are proximal to the catalytic center (S216) or the template entry 146 channel (T223, S384 and S673) ( Figure 2B ). We also included PB1 S478 given its close proximity 147 to the catalytic center. Phosphorylation at PB1 T223 was identified during infection, confirming 148 and extending the importance of prior work that had identified this phospho-site from transfected 149 cells (Hutchinson et al., 2012) . None of the other phospho-sites have been previously reported. 150
Phosphorylation status of PB1 impacts the ability of the polymerase to produce RNA and 151 infectious virions 152
To assess the biological relevance of these phosphorylation events, we attempted to rescue 153 influenza virus encoding PB1 mutants harboring phospho-mimetic aspartic acid (D) or phospho-154 ablative alanine (A) mutations. All tested phospho-ablative PB1 constructs produced virus, 155 whereas phospho-mimetic mutants at PB1 T223, S478 and S673 failed to yield virus despite 156 multiple attempts. For PB1 mutants that support production of infectious virus, we measured viral 157 gene expression during single-cycle infection of A549 cells ( Figure 3A ). Phospho-ablative mutants 158 produced similar amounts of NP mRNA compared to WT, with the exception of PB1 T223A that 159 had decreased transcription and PB1 S673A that exhibited a significant 5-fold increase in gene expression. Phospho-mimetic mutants displayed more subtle phenotypes, with PB1 S216D 161 slightly above and PB1 S384D was slightly below WT levels. These viruses were then assayed 162 in a multi-cycle replication assay ( Figure 3B ). All viruses exhibited roughly similar replication 163 kinetics at 12 and 24 hpi. However, PB1 T223A plateaued at peak titers ~10-fold lower than WT 164 and the titers of PB1 S478A and S673A rapidly declined at 72 and 96 hpi to yield final titers ~10-165 fold lower than WT. PB1 harboring phospho-mimetics at position S216 and S384 yielded virus 166 that replicates similar to WT virus despite producing disparate levels of NP transcripts ( Figure 3A -167 B). Constitutive phosphorylation at PB1 T223, S478, and S673 is incompatible with production of 168 infectious virus, whereas the complete loss of phosphorylation at positions PB1 T223 and S673 169 also disrupts transcription and viral replication. These data suggest that differential 170 phosphorylation of PB1 is important for successful infection. 171
Replication assays revealed PB1 phospho-residues important for the infectious cycle. We next 172 focused solely on polymerase activity by performing primer extension assay for polymerases 173 containing WT or phospho-mutant PB1 ( Figure 4A Remarkably, PB1 S673D replicated viral RNA, but showed a severe reduction in mRNA. 181
Transcriptional defects for PB1 S673D were as strong as the previously described transcriptional 182 mutant PB1 K669A/R670A ( Figure 4A data suggest that phosphorylation at PB1 S673 biases plus-sense RNA synthesis away from 184 transcription and towards replication. PB1 S216D, S384D, and S673A generated transcription 185 and replication products similar to WT PB1. Some of the differences in transcription detected 186 during single-cycle infection ( Figure 3A) were not fully recapitulated in primer extension assays 187 ( Figure 4A ). This could be explained by the simplified nature of primer extension assays that lack 188 viral factors that may modulate RNA production during infection (Robb et al., 2009) . 189
Polymerase activity requires multiple steps for successful replication and transcription, beginning 190 with protein expression, trimer assembly, RNA binding, RNP assembly, and ultimately the 191 synthesis of new RNA products (Fodor and te Velthuis, 2019). Primer extension reports on the 192 cumulative success of this process. We therefore systematically investigated each step to identify 193 regulatory points affected by PB1 phosphorylation. PB1 stability and polymerase trimer formation 194 were assayed by expressing proteins in cells, immuno-purifying PB1, and probing for co-195 precipitating PB2 and PA ( Figure 4B ). All PB1 mutants expressed and formed trimers at 196 approximately WT levels, independent of whether they were phospho-ablative or phospho-197 mimetic. Thus, phosphorylation of PB1 at these sites does not control trimer assembly. 198
Additionally, as polymerase trimers form in the cell nucleus, these data imply that defects in RNA 199 production are not due to faulty nuclear import of polymerase subunits (Deng et al., 2005) . RNP 200 assembly was next investigated by expressing RNP components in cells, immuno-precipitating 201 NP and probing for co-precipitating polymerase ( Figure 4C ). Active polymerase will replicate the 202 viral genome and amplify RNP assembly. We therefore utilized the catalytically dead PB1a to 203 measure initial RNP formation that is independent of polymerase activity. PB1 mutants with 204 defects in polymerase activity in primer extension assays failed to form productive RNPs, but the 205 extent of the defect suggests different causes. PB1 T223D was completely excluded from RNPs, 206 despite that fact that it forms trimers, suggesting phosphorylation at this position precludes 207 incorporation into an RNP. PB1 S478D, however, assembled RNPs at low levels comparably to 208 PB1a, indicating that RNP assembly per se is unaffected by this mutant. Rather, RNP assembly 209 defects here stem from catalytic defects in the polymerase and not other steps in the process. 210
The PB1 S673D phospho-mimetic do not alter RNP assembly, consistent with its ability to 211 synthesize WT levels of genomic RNAs. In sum, loss of phosphorylation did not alter assembly 212 and activity of RNPs in these assay. Conversely, mimicking constitutive phosphorylation at PB1 213 T223 or PB1 S478 prevented formation of productive RNPs and disrupted RNA synthesis. Finally, 214 phosphorylation at PB1 S673 appears to toggle the viral polymerase primarily into replication 215 mode. 216
PB1 T223 phosphorylation inhibits vRNA binding and cRNA stabilization 217
Incoming RNPs synthesize both viral mRNA and cRNA, but cRNA is rapidly degraded; the 218 polymerase and NP that would assemble into RNPs and protect cRNA from degradation have not 219 yet been synthesized (Vreede et al., 2004 ). Whereas PB1 S478D was able to form low levels of 220 RNPs, the complete failure of PB1 T223D was suggestive of defects in RNA binding. To test this 221 possibility, we examined whether PB1 mutants could bind and stabilize cRNA during infection 222 ( Figure 5A ). Polymerase with WT or mutant PB1 was expressed in cells prior to infection with WT 223 virus. The oligomerization-deficient NPE339A was also pre-expressed to help stabilize cRNA while 224 focusing the assay only on RNA made from the incoming RNPs. Cells were treated with 225 actinomycin D during infection so only pre-expressed viral proteins were present. Primer 226 extension showed that cRNA was stabilized by WT PB1 as expected (Vreede et al., 2004) . Figure 4A ), still stabilized cRNA yielding levels slightly higher than WT 230 ( Figure 5A ). PB1 T223A also showed a minor increase in cRNA levels. However, polymerases 231 with PB1 T223D exhibited a significant drop in cRNA stabilization. All of the other phospho-mutant 232 polymerases stabilized cRNA to WT levels, consistent with their ability to replicate viral RNA. This 233 was true even for PB1 S673D, which is replication competent but produces lower levels of mRNA 234 ( Figure 4A) . 235 Viral RNA promoter binding is essential for stabilizing genomic RNA, suggesting that mimicking 236 phosphorylation at PB1 T223 interferes with RNA binding. RNA immunoprecipitation assays were 237 performed to measure promoter binding ( Figure 5B ). Polymerase and segment 6 vRNA were 238 expressed in cells and polymerase was purified by immunoprecipitating PB1. Co-precipitating 239 vRNA was detected by primer extension. vRNA co-purified with WT PB1, but not in its absence 240 or when all polymerase subunits were excluded from the assay. PB1 T223D completely failed to 241 bind vRNA, even though vRNA was readily detected for PB1 T223A. PB1 S478D bound vRNA, 242 consistent with its ability to stabilize cRNA and form low levels of RNPs. If anything, PB1 S478D 243 showed higher binding than both WT and PB1 S478A. These data parallel those from the 244 stabilization assays. Multiple lines of investigation identify discrete defects caused by mimicking 245 phosphorylation. Constitutive phosphorylation at PB1 S478 appears to disrupt catalysis without 246 affecting RNA binding or initial RNP formation. Conversely, PB1 T223D was unable to stabilize 247 cRNA or bind vRNA, suggesting that its inability to assemble RNPs and synthesize viral RNAs 248 arises from defects in template binding. 249
Discussion 250
Multiple mechanisms converge to regulate the influenza polymerase and bias production of either 251 transcripts, the replication intermediate cRNA, or genomic vRNA. Here we reveal that 252 phosphorylation of the polymerase directly regulates its activity. The core polymerase subunit 253 PB1 was phosphorylated at multiple conserved sites, with clusters proximal to the catalytic center 254 or the template entry channel. Mimicking phosphorylation at PB1 S478 or T223 disrupted global 255 polymerase function by affecting catalytic activity or template binding, respectively. By contrast, 256 phosphorylation at PB1 S673 preferentially suppressed transcription to create a replicase form of 257 the polymerase. In all cases, mimicking phosphorylation at these key sites blocked the production 258 of infectious virus, whereas ablating phosphorylation led to defects in replication. These data 259 demonstrate that phosphorylation directly controls polymerase activity by either inhibiting or 260 regulating RNA production. 261
The influenza polymerase performs diverse functions as transcription peaks early in infection, 262 Alternatively, basic residues K669, R670 and R672 in this region had previously been shown to 284 be important for transcription and activating cap binding by PB2, but not replication (Kerry et al., 285 2008) . Perhaps phosphorylation at S673 partially neutralizes their charge to reveal the same 286 phenotype as when these basic residues were mutated to alanine. Independent of the exact 287 molecular mechanism, phosphorylation at PB1 S673 could be a way to establish replicase-288 specific polymerases. 289
PKCd interacts with the viral polymerase and modifies NP to control RNP assembly (Mondal et 290 al., 2017) . Here we showed that phosphorylation was identified on PB1 S478 in cells expressing 291 active PKCd. Mutational analysis revealed that the phospho-mimetic PB1 S478D is functionally 292 analogous to the well-characterized PB1a allele that mutates the conserved SDD motif in the 293 active site: PB1 S478D retains the ability to bind the viral promoter, stabilizes cRNA, and forms 294 initial RNPs, but is catalytically inactive (Figure 4 Our studies reveal that constitutive phosphorylation largely inhibits specific polymerase functions, 299 whereas phospho-ablative mutants are more tolerated. Phospho-ablative mutants at PB1 T223, 300 S478 and S673 retained polymerase function, but exhibit dysregulated abundance and altered 301 replication profiles (Figure 3) . These data suggest that balanced phosphorylation at these 302 positions is important for normal polymerase output. The phospho-sites are all located at sites 303 that are not immediately on the surface of the trimeric polymerase. This suggests kinases modify 304 PB1 during its translation or assembly into the trimer. It further raises the possibility that these 305 incubated for 1 hr at 42⁰ C. Reactions were terminated with an equal volume of 2x RNA loading 371 dye (47.5% formamide, 0.01% SDS, 0.5 mM EDTA containing bromophenol blue and xylene 372 cyanol), boiled for 2 mins and snap-chilled on ice prior to resolving on 6% (full-length templates) 373 or 12% (short templates) denaturing polyacrylamide gels containing 0.5X TBE and 7M Urea. Gels 374 were fixed (40% methanol, 10% acetic acid, 5% glycerol) for 30 mins, dried, quantified by 375 phosphorimaging, and analyzed using Image Studio software (Licor). 376 377
Preparation of samples for mass spectrometry: 378
Mass spectrometry was performed on both transfected and infected cells. HEK 293T cells (3 x 379 100mm dishes containing approximately 6x10 6 cells) were transfected to express PB1, FLAG-380 tagged PB2, PA and vNP76 (Turrell et al., 2013) . 24 hr later, cells were lysed in RIPA Buffer (150mM NaCl, 50mM Tris pH 7.5, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS, 1% w/v Ipegal 382 630, 2mM EDTA) in the presence of protease inhibitors and phosphatase inhibitors for 20 mins 383 at 4⁰C. Lysates were sonicated and then cleared via centrifugation at 4⁰ C. FLAG-tagged PB2 384 was immunoprecipated using M2 antibody overnight at 4⁰ C. Immunocomplexes were captured 385 using protein A dynabeads (Invitrogen 10002D) for 2 hr. Immunoprecipitations were washed twice 386 with RIPA buffer and 4 times with NTE (100mM NaCl, 10mM Tris pH 7.5, 1mM EDTA). Protein 387 was eluted with 8M urea in NTE. Samples were frozen at -80⁰ C prior to mass spectrometric 388
analysis. 389
For samples prepared from virally-infected cells, A549 cells were synchronously infected with 390 WSN at an MOI of 5. Cells were collected at 2.5 hpi (30x10 6 cells), 5 hpi (18x10 6 cells), 7.5 hpi 391 (18x10 6 cells), and 10 hpi (12x10 6 cells). Cell numbers were adjusted in an attempt to account for 392 lower amounts of viral proteins early during infection. Cells were scraped into ice-chilled PBS and 393 collected by centrifugation. NP immunoprecipitations were performed as above using α-NP 394 monoclonal antibody H16-L10-4R5. Samples were also prepared using the same approach in 395 separate experiments where A549 cells were infected with WSN at an MOI of 0.1 for 24 hr or an 396 MOI of 5 for 6hr. Cell pellets and immunoprecipitations were frozen at -80⁰ C prior to mass 397 spectrometric analysis. 398
Mass spectrometry 399
Sample preparation for Nano-LC-MS/MS 400 Infected cells were lysed in 6M guanidine-HCl for 10 min at 100 °C. Protein was precipitated by 401 addition of methanol to a final concentration of 90% and pelleted by centrifugation at 12,000 x G 402 for 10 min. The supernatant was discarded and pellet was resuspended in 8M urea, 50 mM Tris 403 (pH 8.0), 10 mM tris(2-carboxyethyl)phosphine) (TCEP) and 40 mM chloroacetamide and 404 rocked at room temperature for 30 min to reduce and alkylate cysteines. The sample was 405 diluted to a urea concentration of less than 1.5 M with 50 mM Tris (pH 8.0) before adding 406 protease grade trypsin (Promega) at an enzyme:protein ratio of 1:50 (mg:mg). The samples 407 were rocked overnight at room temperature during the digestion. 10% trifluoroacetic acid was 408 added to the solution to bring the pH of the sample less than 2 before desalting and peptide 409 isolation using Strata-X reverse phase resin (Phenomenex). Sample were dried under reduced 410 pressure, resuspended in 0.2% formic acid, and quantified by Pierce Quantiative Colorimetric 411
Peptide Assay (Thermo Fisher Scientific). Phosphopeptides were enriched for each sample 412 from 2 mg tryptic peptides using immobilized metal affinity chromatography (Ti-IMAC 413
MagResyn, ReSyn Biosciences). 414
Nano-LC-MS/MS Data Acquisition 415
Each sample was analyzed using an Q-LTQ-OT tribrid mass spectrometer (Orbitrap Fusion ∆PB1  WT  S216A  S216D  S478A  S478D  T223A  T223D  S384A  S384D S673A S673D PB1a  WT  T223A  T223D  S384A  S384D  S673A A. Viral RNA synthesis was analyzed in primer extensions assays. RNA extracted from 293T cells expressing the viral polymerase, NP, and segment 6 vRNA was subject to primer extension analysis to detect transcription (mRNA) and replication (cRNA, vRNA) products. Primer extension of 5S rRNA was used as an internal loading control. PB1a, catalytically-dead PB1; PB1 K669A/R670A, transcription-deficient PB1. B. PB1 phospho-mutants form polymerase trimers. FLAG-tagged PB1, PB2, and PA were expressed in 293T cells and cell lysates were subject to PB1-FLAG immunoprecipitation.
Immunoprecipitates and input samples were probed for PB1-FLAG, PB2, and PA. C. PB1 phospho-mimetics deficient in RNA synthesis fail to generate productive RNPs. NP immunoprecipitations were performed on 293T lysates generated as in (A). Immunoprecipitates and input samples were western blotted for PB1, PA, and NP. Figure 5 : Phosphorylation at T223 inhibits cRNA stabilization and vRNA binding. A. PB1 phospho-mutants were tested in a cRNA stabilization assay. WT or mutant PB1 and oligomerization-deficient NP (NPE339A) were expressed in 293T cells. Cells were treated with actinomyocin D (ActD) prior to infection, RNA extraction and primer extension analysis to detect transcription (mRNA) and replication (cRNA, vRNA) products. A representative primer extension gel is shown. cRNA levels were quantified, normalized to WT, and expressed as mean ± sd. * < 0.05, ** < 0.01, *** < 0.001 = P for one-way ANOVA with Dunnett's post hoc compared to WT. B. PB1 T223D fails to precipitate vRNA in an RNA-IP (RIP). PB1-FLAG, PB2, PA, and segment 6 vRNA were expressed in 293T cells. Cells were lysed and subject to FLAG immunoprecipitation. RNA extracted from immunoprecipitates and input samples was probed for the presence of segment 6 vRNA via primer extension analysis. Immunoprecipitated PB1 was confirmed via western blot. vRNA levels were quantified from three independent stabilization assays and normalized to WT. Data are presented at mean ± sd. There was no significant difference when analyzed by a one-way ANOVA.
